. 2022 Apr 4;9(2):88–92. doi: 10.5152/eurjrheum.2022.21063
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.Table 1.
Patient Characteristics in Study Cohorts
| Patient Characteristics | Rituximab | Cyclophosphamide |
|---|---|---|
| Age (years) | 43 (13) | 47 (15) |
| Mean (SD) | ||
| Sex Number (percent) | ||
| Male | 19 (48%) | 27 (51%) |
| Female | 20 (52%) | 26 (49%) |
| Baseline BVAS, mean (SD) | 7.77 (1.01) | 7.21 (1.63) |
| Disease duration (years), mean (SD) | 3.46 (2.1) | 3.75 (1.98) |
| Comorbidities, N (%) | 10 (37%) a | 9 (31%) b |
| Serum Cr | 1.6 (1.9) | 2.4 (3.3) |
| ESR | 62.5 (32.3) | 72.9 (35.2) |
| CRP | 52.3 (38.4) | 61.1 (35.6) |
| Total, N (%) | 39 (42.4%) | 53 (57.6%) |
aDiabetes: three patients; hypertension: three patients; hypothyroidism: two patients; peptic ulcer: one patient; migraine: one patient.
bHypertension: two patients; diabetes: three patients; hypothyroidism: one patient; disk herniation: one patient; coronary artery disease: two patients.
BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SD, standard deviation.